{"id":28,"date":"2023-07-04T15:08:19","date_gmt":"2023-07-04T14:08:19","guid":{"rendered":"http:\/\/tris.sambrownprojects.com\/?page_id=28"},"modified":"2024-08-13T03:31:36","modified_gmt":"2024-08-13T07:31:36","slug":"adhd","status":"publish","type":"page","link":"https:\/\/www.trispharma.com\/innovation\/adhd\/","title":{"rendered":"ADHD"},"content":{"rendered":"
[vc_row full_width=”stretch_row” video_bg=”yes” video_bg_url=”\/wp-content\/uploads\/2024\/04\/ADHD-Background.mp4″ conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”video-bl-bg grad-over-video adj-video” css=”.vc_custom_1723534287485{background-image: url(https:\/\/www.trispharma.com\/wp-content\/uploads\/2024\/08\/ADHD-Background.jpg?id=3109) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column width=”1\/2″][\/vc_column][vc_column width=”1\/2″ el_class=”col-bl-bg” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column_text el_class=”text-inno text-white”]<\/p>\n
[\/vc_column_text][vc_column_text css=”.vc_custom_1713449561309{margin-bottom: 0px !important;}” el_class=”text-white”]Many available attention-deficit\/hyperactivity disorder (ADHD) therapies are associated with significant drawbacks that create additional burden for patients. Our portfolio of leading ADHD medicines harnesses the innovative capabilities of our proprietary LiquiXR<\/em>\u00ae<\/sup> technology to reduce these drawbacks and improve treatment outcomes for adults and children with ADHD.[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” wrap_container=”yes” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”subpage-nav hide-mobile”][vc_column] [\/vc_column_text][vc_column_text css=”.vc_custom_1716871491531{margin-bottom: 0px !important;}”]Living with ADHD can be a debilitating struggle that can cause mood swings and impulsiveness, and make it difficult to pay attention. Untreated ADHD symptoms can have a significant negative impact across an individual’s daily life, including school and work performance, as well as the quality of social interactions and relationships.1<\/a><\/sup> Medication can help patients function better throughout the day; however, many approved treatments don\u2019t meet all the needs of ADHD patients for flexibility, consistency and duration of effect.<\/p>\n Our flexible technology, which is designed around the needs of patients, differentiates our portfolio of five leading ADHD therapies that encompass a range of multiple delivery options uniquely tailored to patients\u2019 needs.[\/vc_column_text][\/vc_column][\/vc_row][vc_row animation_duration=”3000″ css=”.vc_custom_1713441838752{margin-top: 20px !important;margin-bottom: 35px !important;}” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column css=”.vc_custom_1631805209511{margin-right: 0px !important;margin-left: 0px !important;padding-right: 0px !important;padding-left: 0px !important;}”][vc_column_text]<\/p>\n [\/vc_column_text][vc_accordion active_tab=”” collapsible=”yes” type=”custom” size=”panel-group-lg” skin=”primary” use_accordion=”true” el_class=”collapsible-panel”][vc_accordion_tab title=”The Patient Profile” el_id=”accordion-dropdown”][vc_column_text css=”.vc_custom_1714555667734{padding-top: 50px !important;padding-bottom: 10px !important;}” el_class=”collapsible-panel-body-copy two-column-textbox-right text-white”]<\/p>\n [\/vc_column_text][\/vc_accordion_tab][\/vc_accordion][\/vc_column][\/vc_row][vc_row animation_duration=”3000″ css=”.vc_custom_1713446658058{margin-top: 20px !important;margin-bottom: 74px !important;}” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column css=”.vc_custom_1631805209511{margin-right: 0px !important;margin-left: 0px !important;padding-right: 0px !important;padding-left: 0px !important;}”][vc_accordion active_tab=”” collapsible=”yes” type=”custom” size=”panel-group-lg” skin=”primary” use_accordion=”true” el_class=”collapsible-panel collapsible-panel-light”][vc_accordion_tab title=”The Impact of ADHD”][vc_column_text css=”.vc_custom_1716867463894{padding-top: 50px !important;padding-bottom: 10px !important;}” el_class=”collapsible-panel-body-copy two-column-textbox-right text-white”]<\/p>\n [\/vc_column_text][\/vc_accordion_tab][\/vc_accordion][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” el_class=”mole-dark-bg” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column_text css=”.vc_custom_1714030317577{padding-top: 0px !important;}” el_class=”text-white list-sup-white”]<\/p>\n [\/vc_column_text][vc_row_inner][vc_column_inner el_class=”col-check” width=”7\/12″] Our proprietary LiquiXR<\/em>\u00ae<\/sup> technology allows us to create ADHD medications in a variety of formulations that are flexible and allow precise, consistent drug release to patients despite their individual needs and differences. This patented technology is built around a unique diffusion coating. When the coating is applied in many different thicknesses to carrier particles with the drug attached, the therapy can be tailored to provide a consistent and continuous release of medication over a targeted duration.[\/vc_column_text] [\/vc_column_text][\/vc_column][vc_column width=”1\/2″][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":" [vc_row full_width=”stretch_row” video_bg=”yes” video_bg_url=”\/wp-content\/uploads\/2024\/04\/ADHD-Background.mp4″ conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”video-bl-bg grad-over-video adj-video” css=”.vc_custom_1723534287485{background-image: url(https:\/\/www.trispharma.com\/wp-content\/uploads\/2024\/08\/ADHD-Background.jpg?id=3109) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_column width=”1\/2″][\/vc_column][vc_column width=”1\/2″ el_class=”col-bl-bg” conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D”][vc_column_text el_class=”text-inno text-white”] People with ADHD deserve medications that offer flexibility and longer lasting benefit [\/vc_column_text][vc_column_text css=”.vc_custom_1713449561309{margin-bottom: 0px !important;}” el_class=”text-white”]Many available attention-deficit\/hyperactivity disorder (ADHD) therapies are associated with significant drawbacks that create additional burden for […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":24,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-28","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nUnderstanding ADHD is critical to improving outcomes<\/h2>\n
How Well Do You Know ADHD?<\/h2>\n
\n
\n
\n
\n
Our LiquiXR\u00ae<\/sup><\/em> technology allows for medicines that:8-9<\/a><\/sup><\/h2>\n
The LiquiXR<\/em>\u00ae<\/sup> difference: continuous delivery to address patient variability<\/h2>\n
\n2<\/sup> Bitsko R., Claussen A., Lichstein J., et al. (2022). Mental Health Surveillance Among Children \u2014 United States, 2013\u20132019. MMWR<\/em>. Suppl 2022;71(Suppl-2):1\u201342.
\n3<\/sup> Ginsberg, Y., Quintero, J., Anand, E., et al. (2014). Underdiagnosis of attention-deficit\/hyperactivity disorder in adult patients: a review of the literature. The primary care companion for CNS disorders<\/em>, 16(3), PCC.13r01600.
\n4<\/sup> Gershon, J., & Gershon, J. (2002). A Meta-Analytic Review of Gender Differences in ADHD. Journal of Attention Disorders<\/em>, 5(3), 143-154. https:\/\/doi.org\/10.1177\/108705470200500302
\n5<\/sup> Barkley, R. A., Murphy, K. R., Dupaul, G. I., & Bush, T. (2002). Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. Journal of the International Neuropsychological Society (JINS)<\/em>, 8(5), 655\u2013672.
\n6<\/sup> Matza, L. S., Paramore, C., & Prasad, M. (2005). A review of the economic burden of ADHD. Cost Effectiveness and Resource Allocation: C\/E, 3,5.
\n7<\/sup> Faraone, S.V., Larsson, H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry<\/em> 24, 562\u2013575 (2019). https:\/\/doi.org\/10.1038\/s41380-018-0070-0
\n8<\/sup> Pardo A, Kando JC, King TR, Rafla E, Herman BK. Single-dose pharmacokinetics of amphetamine extended-release tablets compared with amphetamine extended-release oral suspension.\u00a0CNS Spectr<\/em>. 2020;25(6):774-781.
\n9<\/sup> Kando JC, King TR, Pardo A. A novel, modified release drug delivery technology containing amphetamine and methylphenidate ion-exchange complexes. Poster presented at American Psychiatric Association Annual Meeting; May 1-3, 2021.[\/vc_column_text][\/vc_column][\/vc_row][vc_row full_width=”stretch_row” wrap_container=”yes” parallax=”content-moving” parallax_speed_bg=”1.2″ conditional_render=”%5B%7B%22value_role%22%3A%22administrator%22%7D%5D” el_class=”gradient-global bottom-collout-adhd mob-footercallout bottom-collout”][vc_column width=”1\/2″][vc_column_text css=”.vc_custom_1714557719068{padding-top: 60px !important;padding-bottom: 60px !important;}” el_class=”text-white quote-width”]<\/p>\nDelivering ADHD treatments designed to provide more favorable results with flexible administration.<\/h2>\n